SAN DIEGO, Nov. 5, 2019 /PRNewswire/ -- DelMar
Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the
"Company"), a biopharmaceutical company focused on the development
of new cancer therapies, today announced it will host a cocktail
reception featuring a panel discussion of Delmar's glioblastoma
multiforme (GBM) trial status with highly recognized thought
leaders in GBM during the 2019 Society for NeuroOncology Annual
Meeting in Phoenix, Ariz.
The event will be held on November 22,
2019 at 4:15-5:30 PM MT at the
JW Marriott Desert Ridge, 5350 E. Marriott Drive in Phoenix Ariz. in the Grand Sonoran Room (H-I).
Panel participants to include:
- John de Groot, M.D.,
professor and chairman ad interim, Department of Neuro-Oncology at
The University of Texas M.D. Anderson
Cancer Center
- David Reardon,
M.D., clinical director of the Center for Neuro-Oncology
at the Dana Farber Cancer Institute and professor of Medicine at
Harvard Medical School
- Timothy Cloughesy,
M.D., professor of neurology at the David Geffen School of
Medicine at the University of California, Los
Angeles and member of the UCLA Brain Research Institute and
Jonsson Comprehensive Cancer Center.
- Nicholas Butowski,
M.D., neuro-oncologist practicing at UCSF Medical
Center in San Francisco,
Calif. and director of translational research in
neuro-oncology at the Brain Tumor Center
- Zhong-ping Chen, M.D., founder chairman of the
Department of Neurosurgery/Neuro-oncology at Sun Yat-sen University
Cancer Center, China and lead
investigator of the Company's Phase 2 clinical trial of VAL-083 in
first-line treatment of MGMT-unmethylated GBM
- Naureen Quibria, Ph.D., Equity Research Associate,
Maxim Group - Moderator
For information or to sign up to attend this event, please send
an email request to spraill@delmarpharma.com.
A recording of the event's proceedings will be available shortly
following on the Company's website, www.delmarpharma.com.
ABOUT DELMAR PHARMACEUTICALS
Located in San Diego,
California, DelMar is focused on the development and
commercialization of new therapies for cancer patients who have
limited or no treatment options. By focusing on understanding tumor
biology and mechanisms of treatment resistance, the Company
identifies biomarkers to personalize new therapies in indications
where patients are failing, or are unable to tolerate,
standard-of-care treatments.
The Company's current pipeline is based around VAL-083, a
"first-in-class", small-molecule chemotherapeutic with a novel
mechanism of action that has demonstrated clinical activity against
a range of cancers, including central nervous system, ovarian and
other solid tumors (e.g., NSCLC, bladder cancer, head & neck)
in U.S. clinical trials sponsored by the National Cancer Institute
(NCI). Based on DelMar's internal research programs and these prior
NCI-sponsored clinical studies, the Company is conducting clinical
trials to support the development and commercialization of VAL-083
to solve significant unmet medical needs.
VAL-083 is being studied in two collaborator-supported,
biomarker-driven Phase 2 clinical trials for MGMT-unmethylated GBM.
Overcoming MGMT-mediated resistance represents a significant unmet
medical need in the treatment of GBM.
Further information on DelMar's clinical trials can be found on
clinicaltrials.gov:
https://www.clinicaltrials.gov/ct2/results?cond=&term=val-083&cntry1=&state1=&recrs
For additional information, please visit
http://delmarpharma.com/; or contact DelMar Pharmaceuticals
Investor Relations: ir@delmarpharma.com / (604) 629-5989.
SAFE HARBOR STATEMENT
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995, including statements regarding the status of the
Company's clinical trials and the reporting of the
results. Any forward-looking statements contained herein are
based on current expectations but are subject to a number of risks
and uncertainties. The factors that could cause actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to the
Company's ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the Company's
products and technology; the availability of substantial additional
funding for the Company to continue its operations and to conduct
research and development, clinical studies and future product
commercialization; and, the Company's business, research, product
development, regulatory approval, marketing and distribution plans
and strategies. These and other factors are identified and
described in more detail in the Company's filings with the SEC,
including the Company's Annual Report on Form 10-K for the year
ended June 30, 2019, the Company's
Quarterly Reports on Form 10-Q, and the Company's Current Reports
on Form 8-K.
CONTACTS:
Investors:
John
Marco
Managing Director
CORE IR
516-222-2560
johnm@coreir.com
Media:
Jules
Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/delmar-pharmaceuticals-to-host-key-opinion-leader-summit-on-glioblastoma-multiforme-and-the-potential-for-treatment-with-val-083-300951417.html
SOURCE DelMar Pharmaceuticals, Inc.